HRP20040788A2 - Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases - Google Patents
Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseasesInfo
- Publication number
- HRP20040788A2 HRP20040788A2 HRP20040788A HRP20040788A2 HR P20040788 A2 HRP20040788 A2 HR P20040788A2 HR P20040788 A HRP20040788 A HR P20040788A HR P20040788 A2 HRP20040788 A2 HR P20040788A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- cycloalkyl
- hetarylalkyl
- hetaryl
- aralkyl
- Prior art date
Links
- -1 porphyrin platinum compounds Chemical class 0.000 title claims description 35
- 206010028980 Neoplasm Diseases 0.000 title claims description 7
- 201000011510 cancer Diseases 0.000 title claims description 4
- 229940045985 antineoplastic platinum compound Drugs 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 34
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 229910052697 platinum Inorganic materials 0.000 claims description 16
- 150000004032 porphyrins Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 150000003057 platinum Chemical class 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002428 photodynamic therapy Methods 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000005670 electromagnetic radiation Effects 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical class [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 24
- 229910001868 water Inorganic materials 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000003446 ligand Substances 0.000 description 21
- 150000004985 diamines Chemical class 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 150000003935 benzaldehydes Chemical class 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- 206010034972 Photosensitivity reaction Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229960003569 hematoporphyrin Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 208000007578 phototoxic dermatitis Diseases 0.000 description 4
- 231100000018 phototoxicity Toxicity 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 231100000760 phototoxic Toxicity 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- MZIZUJJQABDEAK-XRIGFGBMSA-N ethyl (2S)-2,4-diaminobutanoate dihydrochloride Chemical compound Cl.Cl.CCOC(=O)[C@@H](N)CCN MZIZUJJQABDEAK-XRIGFGBMSA-N 0.000 description 2
- MUFTVIRBUNQPIU-UHFFFAOYSA-N ethyl 2,3-diaminopropanoate;dihydrochloride Chemical compound Cl.Cl.CCOC(=O)C(N)CN MUFTVIRBUNQPIU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- LQBPATQBTSBIIH-UHFFFAOYSA-N methyl 3-[8,13-bis(ethenyl)-18-(3-methoxy-3-oxopropyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoate Chemical compound N1C(C=C2C(=C(C=C)C(=CC=3C(=C(CCC(=O)OC)C(=C4)N=3)C)N2)C)=C(C=C)C(C)=C1C=C1C(C)=C(CCC(=O)OC)C4=N1 LQBPATQBTSBIIH-UHFFFAOYSA-N 0.000 description 2
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical class Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 2
- ZXDJCKVQKCNWEI-UHFFFAOYSA-L platinum(2+);diiodide Chemical compound [I-].[I-].[Pt+2] ZXDJCKVQKCNWEI-UHFFFAOYSA-L 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000004427 diamine group Chemical group 0.000 description 1
- ZGZOLSPBOBHGLF-UHFFFAOYSA-N diethyl 2-(4-formylphenoxy)propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)OC1=CC=C(C=O)C=C1 ZGZOLSPBOBHGLF-UHFFFAOYSA-N 0.000 description 1
- FNJVDWXUKLTFFL-UHFFFAOYSA-N diethyl 2-bromopropanedioate Chemical compound CCOC(=O)C(Br)C(=O)OCC FNJVDWXUKLTFFL-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- RPWLHEQRWJGHJP-UHFFFAOYSA-N ethyl 2,3-diaminobutanoate Chemical compound CCOC(=O)C(N)C(C)N RPWLHEQRWJGHJP-UHFFFAOYSA-N 0.000 description 1
- UHPCBUYSHWNREK-UHFFFAOYSA-N ethyl 2,3-diaminopropanoate Chemical compound CCOC(=O)C(N)CN UHPCBUYSHWNREK-UHFFFAOYSA-N 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 150000004034 porphyrinogens Chemical class 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyethers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35358502P | 2002-02-01 | 2002-02-01 | |
| PCT/EP2003/000874 WO2003064424A2 (en) | 2002-02-01 | 2003-01-29 | Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040788A2 true HRP20040788A2 (en) | 2004-12-31 |
Family
ID=27663224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20040788 HRP20040788A2 (en) | 2002-02-01 | 2004-08-30 | Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7087214B2 (ja) |
| EP (1) | EP1470139A2 (ja) |
| JP (1) | JP2005522429A (ja) |
| KR (1) | KR20040083098A (ja) |
| CN (1) | CN1303090C (ja) |
| AR (1) | AR038479A1 (ja) |
| BR (1) | BR0307400A (ja) |
| CA (1) | CA2418410A1 (ja) |
| HK (1) | HK1078585A1 (ja) |
| HR (1) | HRP20040788A2 (ja) |
| MX (1) | MXPA04007443A (ja) |
| NO (1) | NO20043650L (ja) |
| NZ (1) | NZ534541A (ja) |
| PL (1) | PL373346A1 (ja) |
| RU (1) | RU2004126637A (ja) |
| TW (1) | TWI233929B (ja) |
| UA (1) | UA78007C2 (ja) |
| WO (1) | WO2003064424A2 (ja) |
| ZA (1) | ZA200405925B (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6995260B2 (en) * | 2004-05-20 | 2006-02-07 | Brookhaven Science Associates, Llc | Carboranylporphyrins and uses thereof |
| US8287839B2 (en) * | 2006-12-04 | 2012-10-16 | Brookhaven Science Associates, Llc | Carboranylporphyrins and uses thereof |
| EP1950217A1 (en) * | 2007-01-26 | 2008-07-30 | Université de Neuchâtel | Organometallic compounds for the treatment of cancer |
| US8444953B2 (en) * | 2007-03-22 | 2013-05-21 | Brookhaven Science Associates, Llc | Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof |
| US20080279781A1 (en) * | 2007-05-10 | 2008-11-13 | Brookhaven Science Associates, Llc | Glycosylated Carboranylporphyrins and Uses Thereof |
| CN103003282B (zh) * | 2010-01-22 | 2016-01-20 | 科学与工业研究会 | 一种制备新的卟啉衍生物的方法及其作为pdt试剂和荧光探针的用途 |
| CN102408452B (zh) * | 2011-12-13 | 2014-09-03 | 中山大学 | 四吡啶基卟啉桥联十字形四核铂配合物及其制备方法和抗肿瘤活性 |
| US10766915B2 (en) | 2013-03-15 | 2020-09-08 | Sherri Ann McFARLAND | Metal-based coordination complexes as photodynamic compounds and their use |
| US11661433B2 (en) | 2018-05-09 | 2023-05-30 | Virginia Commonwealth University | Near-IR activatable fluorescent small molecules with dual modes of cytotoxicity |
| CN109251206B (zh) * | 2018-09-21 | 2022-02-08 | 上海大学 | 水溶性铂-卟啉配合物及其制备方法 |
| CN110028513B (zh) * | 2019-04-30 | 2020-12-11 | 北京太阳升高科医药研究股份有限公司 | 卟啉衍生物及声敏剂 |
| CN110590852B (zh) * | 2019-08-29 | 2022-12-09 | 合肥学院 | 一种具有抗肿瘤活性的铂配合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0615545B2 (ja) * | 1984-10-01 | 1994-03-02 | 東洋薄荷工業株式会社 | 金属フェオホーバイド誘導体および金属ポルフィリン誘導体 |
| ZA86704B (en) | 1985-02-23 | 1986-10-29 | Asta Werke Ag Chem Fab | Tumor retarding(1-benzyl-ethylenediamine9-platin(ii)-complexes |
| DE3687399T2 (de) * | 1985-10-23 | 1993-04-29 | Nihon Mediphysics Co Ltd | Porphyrinderivate, ihre herstellung und verwendung. |
| DE19824653A1 (de) | 1998-02-25 | 1999-08-26 | Schering Ag | Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie |
-
2003
- 2003-01-27 US US10/353,788 patent/US7087214B2/en not_active Expired - Fee Related
- 2003-01-29 NZ NZ534541A patent/NZ534541A/en unknown
- 2003-01-29 KR KR10-2004-7011734A patent/KR20040083098A/ko not_active Application Discontinuation
- 2003-01-29 CN CNB038045524A patent/CN1303090C/zh not_active Expired - Fee Related
- 2003-01-29 BR BR0307400-5A patent/BR0307400A/pt not_active IP Right Cessation
- 2003-01-29 RU RU2004126637/04A patent/RU2004126637A/ru not_active Application Discontinuation
- 2003-01-29 EP EP03734604A patent/EP1470139A2/en not_active Withdrawn
- 2003-01-29 JP JP2003564047A patent/JP2005522429A/ja not_active Withdrawn
- 2003-01-29 WO PCT/EP2003/000874 patent/WO2003064424A2/en not_active Application Discontinuation
- 2003-01-29 UA UA20040806544A patent/UA78007C2/uk unknown
- 2003-01-29 PL PL03373346A patent/PL373346A1/xx unknown
- 2003-02-03 CA CA002418410A patent/CA2418410A1/en not_active Abandoned
- 2003-02-03 AR ARP030100329A patent/AR038479A1/es unknown
- 2003-02-06 TW TW092102414A patent/TWI233929B/zh not_active IP Right Cessation
-
2004
- 2004-07-26 ZA ZA200405925A patent/ZA200405925B/en unknown
- 2004-07-30 MX MXPA04007443A patent/MXPA04007443A/es unknown
- 2004-08-30 HR HRP20040788 patent/HRP20040788A2/hr not_active Application Discontinuation
- 2004-08-31 NO NO20043650A patent/NO20043650L/no not_active Application Discontinuation
-
2005
- 2005-11-18 HK HK05110413A patent/HK1078585A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003064424A3 (en) | 2004-01-15 |
| CN1303090C (zh) | 2007-03-07 |
| BR0307400A (pt) | 2004-12-21 |
| US7087214B2 (en) | 2006-08-08 |
| CN1639178A (zh) | 2005-07-13 |
| NO20043650L (no) | 2004-10-29 |
| JP2005522429A (ja) | 2005-07-28 |
| RU2004126637A (ru) | 2006-02-10 |
| TW200305571A (en) | 2003-11-01 |
| US20040023942A1 (en) | 2004-02-05 |
| TWI233929B (en) | 2005-06-11 |
| PL373346A1 (en) | 2005-08-22 |
| NZ534541A (en) | 2005-10-28 |
| MXPA04007443A (es) | 2004-10-11 |
| AR038479A1 (es) | 2005-01-19 |
| EP1470139A2 (en) | 2004-10-27 |
| UA78007C2 (en) | 2007-02-15 |
| ZA200405925B (en) | 2004-09-07 |
| KR20040083098A (ko) | 2004-09-30 |
| WO2003064424A2 (en) | 2003-08-07 |
| HK1078585A1 (en) | 2006-03-17 |
| CA2418410A1 (en) | 2003-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Recent advances in the synthesis, stability, and activation of platinum (IV) anticancer prodrugs | |
| Haribabu et al. | Water-soluble mono-and binuclear Ru (η6-p-cymene) complexes containing indole thiosemicarbazones: synthesis, DFT modeling, biomolecular interactions, and in vitro anticancer activity through apoptosis | |
| Lottner et al. | Hematoporphyrin-derived soluble porphyrin− platinum conjugates with combined cytotoxic and phototoxic antitumor activity | |
| EP0306605B1 (en) | Antitumor platinum complexes | |
| GB2024823A (en) | Platinum-diamine complexes for use in the treatment of cancer | |
| JP5385923B2 (ja) | Ｎ−複素環式カルベン白金誘導体、この調製、およびこの治療用途 | |
| HU224716B1 (en) | Platinum complex, its preparation and therapeutic application | |
| Mari et al. | Towards Selective Light‐Activated RuII‐Based Prodrug Candidates | |
| JPH04327596A (ja) | 新規トランス−Ｐｔ（ＩＶ）化合物 | |
| Brunner et al. | Carboplatin-containing porphyrin–platinum complexes as cytotoxic and phototoxic antitumor agents | |
| HRP20040788A2 (en) | Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases | |
| JPH09504275A (ja) | トランスプラチナ（▲ｉｖ▼）錯体 | |
| Lari et al. | Strong influence of ancillary ligands containing benzothiazole or benzimidazole rings on cytotoxicity and photoactivation of Ru (II) arene complexes | |
| JPS6368546A (ja) | シス−白金錯化合物およびその製法 | |
| RU2140422C1 (ru) | Трехплатиновые комплексы pt(ii), способ их получения | |
| CA2560059A1 (en) | Platinum carboxylate anticancer compounds | |
| Eren et al. | In Vitro Cytotoxic Activities of Platinum (II) Complex with 1-Methyl-2-(3'-hydroxypropyl) benzimidazole and 2-(3# 39;-Hydroxypropyl) benzimidazolium Hexa-and Tetrachloroplatinate Salts | |
| Hoffmeister et al. | Diamminetetrakis (carboxylato) platinum (IV) complexes–synthesis, characterization, and cytotoxicity | |
| EP0897389A1 (fr) | Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant | |
| EP1473298B1 (en) | Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions | |
| AU2003210192A1 (en) | Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases | |
| US20230024341A1 (en) | Platinum(iv) complexes, methods of manufacture, compositions containing, and methods of use thereof | |
| Brunner et al. | Double porphyrin platinum conjugates | |
| JP2005511497A (ja) | 光反応性化合物および組成物 | |
| US10899781B2 (en) | Platinum complex, its preparation and therapeutic use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: ZENTARIS GMBH, DE |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20070112 Year of fee payment: 5 |
|
| OBST | Application withdrawn |